Avalanche is a biopharmaceutical company committed to improving or preserving the sight of people with serious eye diseases with an unmet medical need. Using a next generation gene therapy platform, the Ocular BioFactory™, the Company is developing product candidates designed to provide long-term efficacy by inducing a sustained expression of a therapeutic protein with the potential for a one-time administration in the eye.
Avalanche Biotechnologies, Inc. Names Paul B. Cleveland as CEO
MENLO PARK, Calif., Nov. 20, 2015 -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today announced the appointment of Paul B. Cleveland to chief executive officer (CEO) and to the Board of Directors effective December 9. He also will serve as principal financial officer of Avalanche on an interim basis. Mr. Cleveland, previously the chief executive officer of Celladon Corporation, brings more than 20 years of leadership experience to Avalanche, including management and operational experience across the biotechnology industry. This includes positions at multiple public biotechnology companies, including CEO, president, chief financial officer and Board member as well as chief operating officer at a venture capital firm. Subsequent to December 9, Hans P. Hull who has been serving as interim CEO of Avalanche since July, will return to his previous role of senior vice president of business operations.
